21th WCC, Shenzhen, China, Aug 19, 2010
Guo-Liang Jiang, MD, FACRGuo-Liang Jiang, MD, FACRMin Fan, MD, Jiayan Chen, MD Min Fan, MD, Jiayan Chen, MD
Fudan University Shanghai Cancer CenterFudan University Shanghai Cancer Center
Combination of radiation therapy and Combination of radiation therapy and Gefitinib for non-small cell lung carcinomaGefitinib for non-small cell lung carcinoma
Outcome of non-small cell carcinomaOutcome of non-small cell carcinoma
Stage and tmt Stage and tmt 55-yr survival -yr survival I-II surgeryI-II surgery 48-70% 48-70%I-II inoperable, SBRT I-II inoperable, SBRT ~~ 40%40%IIIa (surgery ±other Tmt) 15-27%IIIa (surgery ±other Tmt) 15-27%IIIa (RTIIIa (RT ++ Chemo) 14-20%Chemo) 14-20%IIIb (RTIIIb (RT ++ Chemo) 5-7%Chemo) 5-7%
Predominant failure pattern: Local and distant failures
Combination of radiation therapy and Gefitinib for
stage IIIb/IV non-small cell lung carcinoma
Clinical phase I trial
Irradiation dose escalation (NCT00497250)
Gefitinib enhanced radiosensitivity of tumor cells Survival curve of Oral SCC (in vitro)
Shintani S. Int J Cancer 2003; 107:1030–37
• Shoulder of survival curve disappear (inhibition for SLD repair)• Slop of survival curve reduced (intrinsic radiosensitivity increased)
Gefitinib enhanced radiosensitivity of tumor cells GEO (rectal carcinoma) in vivo (tumor re-growth delay) 10Gy/fx×4fx + Iressa 2.5mg ip d1-5×4 wks
Bianco et al. Clin Cancer Res 2002;8:3250-3258
Iressa + RT
Control RTIressa
The percentage of S phase decreased after IressaIressa+RT (GEO in vivo)
Bianco C. Clin Cancer Res 2002;8:3250-3258
Mechanism of Gefitinib radiosensitization
Gefitinib speeds up apoptosis of tumor cells after RT GEO in vivo
Bianco C. Clin Cancer Res 2002;8:3250-3258
RT+Iressa
RT
Iressa
Gefitinib inhibits RT induced damage repairOral SCC (Western blot)
Shintani S. et al. Int J Cancer 2003; 107:1030–1037
RT damage DNA
Need DNA repair enzyme
RT enzyme DNA repair Gefitinib enzyme DNA repair
Iressa+RT in Oral SCC (Western blot)
RT could activate EGFR-TK signaling pathway (Ras-Raf-MAPK). And And initiates a multistep phosphorylation cascade that leads to activation the pathway, and stimulates cell-cycle progression
Shintani S. Int J Cancer 2003; 107:1030–1037
Gefitinib could inhibit multistep phosphorylation of EGFR signaling pathway, so slow down the tumor cell proliferation and enhance the radiation sterilization.
Possible mechanisms for radiosensitization of Gefitinib
1. Decrease percentage of S phase and increase G2/M phases of tumor cells
2. Enhance tumor cell apoptosis after RT 3. Inhibit radiation induced DNA repair4. Inhibit multistep phosphorylation of EGFR
signaling pathway, so reduce the tumor cell proliferation after RT
Rationales:• Gefitinib as radiosensitizer to enhance local tumor
sterilization.• Inhibit or delay the growth of micrometastases
• What is concerned most for concurrent RT and Gefitinib for NSCLC?
• Pulmonary toxicity: Interstitial pneumonitis by Gefitinib Radiation pneumonitis
Goal of the trialMain endpoint Side-effect and toxicity, safety and MTD of
concurrent therapy of Gefitinib and RT for advanced non-small cell lung carcinoma.
Second endpoint Acute response (RECIST) and survival
Patient eligibility
NSCLC histologically or cytologically confirmed
IIIbIV: brain metsECOG 1-2 No contraindication for RT Tolerable for RT and Gefitinib
TreatmentConcurrent Gefitinib (250mg, qd) and RT and continuously Gefitinib for 2 months after RT. RT target: Gross tumor volume in thorax on CT2Gy/fx, 5 fx/wk,Total dose escalation54Gy, 56Gy, 58Gy, 60Gy
Dose limit toxicity (DLT) in 2 months after completion of RTCTCAE V3 >=3 for lungCTCAE V3 >=4 for othersWhen >=2/8 patients occurred DLT, dose escalation terminated and MTD was one dose level before.
ResultStatus of dose escalation
Dose level No. pts
54Gy 8
56Gy 8
58Gy 8
60Gy 8+8
One patient in 60Gy occurred interstitial pneumonitis in both lung one week after RT and died of pulmonary failure in 30 days
Male/Female 28/12Medium age (yr)Medium cycle of chemo
55 (32–79)3.5 (1-5)
ECOG 01
1030
Stage IIIB IV
1822
Histology Adeno-SqPoor differentiated
35 (86%)4
1Smoker/non-smoker 20/20
Clinical characteristics of patients (n=40)
Safety (MFT: 9.7 mos)
CTCAE 3.0 Incidence Rash 1-2 24 (60%)
≥3 0Pulmonary 1-2 29 (73%)
3G5
01 (3%)
Espophageal 1-2 23 (58%) ≥3 0Hematological
1-2 16 (40%)
≥3 0
OutcomeAt last follow-up visitSD 8 (20%); PD 32 (80%)Median progression-free time: 7 mosMedian survival time: 13.9 mos (11.4-16.4)1-yr OS 62%
Conclusion
1. IIIB/IV NSCLC patients could tolerate concurrent RT (MTD 60Gy) and Gefitinib.
2. There was no excessive toxicity in NSCLC patients treated with concurrent RT and daily Gefitinib, except for pulmonary toxicity, which seemed like increased, especially the low grades (1-2) of CTCAE.
3. MST of 13.9 mos and 62% of 1-yr OS were encouraging.
4. Clinical phase II trial was warranted, especially for non-smoker and adnocarcinoma (EGFR mutated).
Thanks for your attention !
Shanghai 2010Shanghai 2010EXPOEXPO